Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	18.59B +194.0%
Revenue (ttm)	2.54B +42.6%
Net Income	304.85M +74.2%
EPS	13.70 +72.3%
Shares Out	22.25M
PE Ratio	61.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	494,869
Open	818.00
Previous Close	796.50
Day's Range	812.10 - 871.30
52-Week Range	306.35 - 871.30
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaestheti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 342
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In fiscal year 2026, Sakar Healthcare's revenue was 2.54 billion, an increase of 42.62% compared to the previous year's 1.78 billion. Earnings were 304.85 million, an increase of 74.18%.